Table 1 Clinicopathological characteristics of invasive breast cancers according to the molecular subtypes
From: Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
Variables | N | Claudin-low | Luminal A | Basal | ERBB2-enriched | Luminal B | Normal-like |
|---|---|---|---|---|---|---|---|
5447 | 673 | 1494 | 1003 | 749 | 1077 | 451 | |
Age at diagnosis, years | Â | Â | Â | Â | Â | Â | Â |
<=50 | 1834 | 238(49%) | 470(43%) | 423(56%) | 224(43%)* | 328(46%)* | 151(53%)* |
>50 | 2005 | 247(51%) | 622(57%) | 331(44%) | 291(57%) | 380(54%) | 134(47%) |
Histological type | Â | Â | Â | Â | Â | Â | Â |
IDC | 1181 | 140(78%) | 263(76%) | 224(88%) | 201(89%) | 255(89%) | 98(84%) |
ILC | 72 | 8(4%) | 34(10%) | 4(2%) | 4(2%) | 12(4%) | 10(9%) |
MED | 24 | 5(3%) | 1(0%) | 18(7%) | 0(0%) | 0(0%) | 0(0%) |
MIX | 59 | 7(4%) | 23(7%) | 4(2%) | 10(4%) | 12(4%) | 3(3%) |
other | 77 | 20(11%) | 26(7%) | 6(2%) | 11(5%) | 8(3%) | 6(5%) |
Histological grade | Â | Â | Â | Â | Â | Â | Â |
1 | 489 | 49(9%) | 293(26%) | 12(2%) | 15(3%) | 53(7%) | 67(21%) |
2 | 1579 | 180(35%) | 605(54%) | 104(14%) | 170(32%) | 367(47%) | 153(48%) |
3 | 1957 | 290(56%) | 222(20%) | 640(85%) | 350(65%) | 358(46%) | 97(31%) |
Pathological tumor size | Â | Â | Â | Â | Â | Â | Â |
pT1 | 928 | 106(38%) | 343(46%) | 130(29%) | 89(27%) | 163(34%) | 97(50%) |
pT2-3 | 1542 | 172(62%) | 399(54%) | 323(71%) | 239(73%) | 311(66%) | 98(50%) |
Pathological axillary lymph node status | Â | Â | Â | Â | Â | Â | Â |
negative | 1907 | 180(54%) | 550(61%) | 379(65%) | 232(51%)* | 387(60%)* | 179(59%)* |
positive | 1313 | 153(46%) | 355(39%) | 200(35%) | 224(49%) | 258(40%) | 123(41%) |
ESR1 expression status | Â | Â | Â | Â | Â | Â | Â |
negative | 1929 | 433(64%) | 80(5%) | 859(86%) | 437(58%) | 24(2%) | 96(21%) |
positive | 3518 | 240(36%) | 1414(95%) | 144(14%) | 312(42%) | 1053(98%) | 355(79%) |
ESR1 mRNA expression, median | 5447 | 6.46 | 10.55 | 5.46 | 7.18 | 10.76 | 9.77 |
PGR expression status | Â | Â | Â | Â | Â | Â | Â |
negative | 2851 | 445(66%) | 386(26%) | 864(86%) | 567(76%) | 443(41%) | 146(32%) |
positive | 2594 | 228(34%) | 1108(74%) | 139(14%) | 181(24%) | 634(59%) | 304(68%) |
PGR mRNA expression, median | 5445 | 4.21 | 5.24 | 3.54 | 4.07 | 4.52 | 5.07 |
ERBB2 expression status | Â | Â | Â | Â | Â | Â | Â |
negative | 4738 | 646(96%) | 1407(94%)* | 958(96%)* | 320(43%) | 1011(94%)* | 396(88%) |
positive | 709 | 27(4%) | 87(6%) | 45(4%) | 429(57%) | 66(6%) | 55(12%) |
ERBB2 mRNA expression, median | 5447 | 6.45 | 7.5 | 6.52 | 8.84 | 7.59 | 7.83 |
Triple-negative expression status | Â | Â | Â | Â | Â | Â | Â |
yes | 1336 | 352(52%) | 22(1%) | 762(76%) | 138(18%) | 13(1%) | 49(11%) |
no | 4110 | 321(48%) | 1472(99%) | 241(24%) | 610(82%) | 1064(99%) | 402(89%) |
Pathological complete response | Â | Â | Â | Â | Â | Â | Â |
pCR | 302 | 73(32%) | 21(7%) | 104(33%)* | 56(37%)* | 40(18%) | 8(14%) |
RD | 992 | 155(68%) | 302(93%) | 210(67%) | 97(63%) | 178(82%) | 50(86%) |
DFS event | Â | Â | Â | Â | Â | Â | Â |
no | 2190 | 223(65%) | 736(75%) | 396(62%)* | 222(52%) | 395(60%)* | 218(73%)* |
yes | 1165 | 120(35%) | 246(25%) | 245(38%) | 205(48%) | 268(40%) | 81(27%) |
5-year DFS [95CI] | 3355 | 67% [0.62-0.73] | 79% [0.77-0.83] | 60% [0.56-0.64] | 55% [0.5-0.6] | 64% [0.6-0.68] | 79% [0.75-0.84] |